関連する実験動画
Updated: May 8, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
肥満の超レプチネミアは,カロリー過剰の肥満調節剤である
1Touchstone Center for Diabetes Research, Department of Internal Medicine, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Y8.212, Dallas, TX 75390, USA.
Cell
|April 16, 2004
まとめ
レプチンとアノレキシゲン薬は,下体内のAMP活性化タンパク質キナーゼ (AMPK) を無効化し,マロニルCoAを増加させることで食欲を低下させます. この研究では,AMPの生物学,マロニル-CoA生成,およびレプチンに関する研究が行われています.
科学分野:
- 神経科学は神経科学である.
- メタボリック・レギュレーション
- 肥満に関する研究
背景:
- レプチンは,エネルギーバランスと食欲を調節する重要なホルモンです.
- 低血圧のAMP活性化タンパク質キナーゼ (AMPK) は食欲のコントロールに重要な役割を果たします.
- マロニルCoAは,脂肪酸合成の中間体であり,エネルギー代謝の調節剤である.
研究 の 目的:
- マロニル-コア生成におけるAMP生物学の役割を検証する.
- レプチンの生理学において,AMPKの中心的な作用と周辺的効果を統合する.
- レプチンおよび関連剤が肥満における食欲を減少させるメカニズムを理解する.
主な方法:
- AMP生物学,マロニル-CoA代謝,およびレプチンシグナル伝達に関する既存の文献のレビュー.
- AMPKの中央と周辺のアクションの相互作用の分析.
- 肥満と食欲の調節の文脈における発見の統合.
主要な成果:
- 証拠によると,レプチンは下垂体AMPKを不活性化させ,マロニルCoA濃度の上昇につながる.
- アノレキシゲン剤によるAMPKの不活性化は食欲抑制に寄与する.
- 食欲制御におけるAMPKの中心的な役割は,周辺の抗脂質毒性機能と関連しています.
結論:
- レプチンの食欲抑制効果は,部分的に,下垂体AMPKの不活性化によって媒介されます.
- AMPKの中央および周辺の作用を理解することは,肥満におけるレプチンの役割を理解するために不可欠です.
- この研究は,肥満管理のためのAMPK-マロニルCoA経路を標的とした新しい治療戦略を調査するための枠組みを提供します.
関連する概念動画
Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

